tiprankstipranks
Trending News
More News >
Fortis Healthcare Ltd. (IN:FORTIS)
:FORTIS
India Market
Advertisement

Fortis Healthcare Ltd. (FORTIS) AI Stock Analysis

Compare
3 Followers

Top Page

IN:FORTIS

Fortis Healthcare Ltd.

(FORTIS)

Rating:75Outperform
Price Target:
₹905.00
▼(-4.38% Downside)
Fortis Healthcare Ltd. receives a strong overall score due to its robust financial performance and favorable technical analysis. The company's consistent revenue growth, improved profitability, and positive market momentum are key strengths. However, the high valuation suggests potential overvaluation, which is a risk factor for investors.

Fortis Healthcare Ltd. (FORTIS) vs. iShares MSCI India ETF (INDA)

Fortis Healthcare Ltd. Business Overview & Revenue Model

Company DescriptionFortis Healthcare Ltd. (FORTIS) is a leading integrated healthcare delivery provider in India, with a presence in multiple countries. The company operates in the healthcare sector and offers a comprehensive range of healthcare services, including primary care, secondary care, tertiary care, and quaternary care. Fortis Healthcare runs a network of hospitals, diagnostics centers, and specialty care facilities, providing services such as surgery, critical care, emergency services, and outpatient care. The company is committed to delivering high-quality healthcare services through its state-of-the-art facilities and skilled medical professionals.
How the Company Makes MoneyFortis Healthcare Ltd. generates revenue primarily through its network of hospitals and healthcare facilities by providing medical and healthcare services to patients. The company's key revenue streams include inpatient and outpatient services, diagnostic services, and specialized medical treatments. Inpatient services generally involve hospital stays for surgical procedures, intensive care, and other medical treatments, which contribute significantly to the company's earnings. Outpatient services include consultations, day-care surgeries, and routine check-ups. Additionally, Fortis Healthcare earns revenue from its diagnostics division, which offers a range of laboratory and imaging services. The company also benefits from strategic partnerships and collaborations with international healthcare providers, which enhance its service offerings and extend its market reach. Revenue is further supported by health insurance tie-ups, making healthcare services accessible to a broader patient base.

Fortis Healthcare Ltd. Financial Statement Overview

Summary
Fortis Healthcare Ltd. demonstrates strong financial performance with consistent revenue growth and improved profitability. The income statement shows robust gross and net profit margins. The balance sheet is stable with a healthy equity ratio, though total debt levels require monitoring. Cash flow is positive with strong cash-generating ability, despite some volatility in capital expenditures.
Income Statement
81
Very Positive
Fortis Healthcare Ltd. has demonstrated a strong income statement performance with consistent revenue growth, particularly from 2021 to 2025. The gross profit margin has remained robust, averaging above 40% in recent years, indicating effective cost management. Net profit margins have improved significantly, turning from negative to positive, showcasing enhanced profitability. EBIT and EBITDA margins have also seen notable improvements, indicating operational efficiency gains.
Balance Sheet
76
Positive
The company's balance sheet is solid with a healthy equity ratio, reflecting financial stability. The debt-to-equity ratio has been improving, suggesting prudent financial management and reduced leverage risk. Return on equity has increased, highlighting better efficiency in generating profits from shareholders' equity. However, the total debt level remains a consideration, though manageable given the company's growth trajectory.
Cash Flow
74
Positive
Fortis Healthcare Ltd. exhibits a positive cash flow trajectory, with significant growth in free cash flow over the years. The operating cash flow to net income ratio indicates strong cash-generating ability relative to accounting profits. However, fluctuations in capital expenditures and investing cash flows highlight potential volatility in future cash flows. Overall, cash flow management appears effective, supporting the company's expansion and operational needs.
BreakdownMar 2025Mar 2024Mar 2022Mar 2023Mar 2021
Income Statement
Total Revenue77.83B68.35B56.39B62.98B39.61B
Gross Profit31.55B22.95B42.21B35.31B21.17B
EBITDA15.88B13.07B14.03B12.29B4.44B
Net Income7.74B5.99B5.55B5.89B-1.10B
Balance Sheet
Total Assets136.92B132.89B118.85B124.34B111.55B
Cash, Cash Equivalents and Short-Term Investments5.08B6.00B4.13B3.94B4.16B
Total Debt24.75B11.55B12.55B9.26B15.31B
Total Liabilities45.22B47.33B48.76B43.33B44.37B
Stockholders Equity89.17B76.63B61.78B72.42B61.20B
Cash Flow
Free Cash Flow5.77B1.58B6.50B3.75B2.67B
Operating Cash Flow14.24B11.00B8.65B8.22B4.85B
Investing Cash Flow-7.79B-9.21B-5.14B-3.74B-1.35B
Financing Cash Flow-7.14B-864.58M-5.17B-4.71B-1.43B

Fortis Healthcare Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price946.50
Price Trends
50DMA
807.80
Positive
100DMA
742.05
Positive
200DMA
695.99
Positive
Market Momentum
MACD
35.52
Negative
RSI
82.98
Negative
STOCH
97.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FORTIS, the sentiment is Positive. The current price of 946.5 is above the 20-day moving average (MA) of 857.77, above the 50-day MA of 807.80, and above the 200-day MA of 695.99, indicating a bullish trend. The MACD of 35.52 indicates Negative momentum. The RSI at 82.98 is Negative, neither overbought nor oversold. The STOCH value of 97.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FORTIS.

Fortis Healthcare Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
₹703.28B80.97
0.11%14.04%32.99%
73
Outperform
₹1.04T66.13
0.26%14.31%51.71%
70
Outperform
₹272.57B52.84
0.73%10.57%34.11%
68
Neutral
₹1.00T52.93
0.04%21.66%-4.92%
68
Neutral
₹370.31B46.93
0.25%12.09%-2.79%
64
Neutral
₹108.55B70.98
0.71%12.86%10.42%
51
Neutral
$7.43B-0.36-45.45%2.27%22.98%-2.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:FORTIS
Fortis Healthcare Ltd.
946.50
425.02
81.50%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
7,808.45
1,306.49
20.09%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
3,294.60
121.25
3.82%
IN:MANKIND
Mankind Pharma Ltd.
2,465.50
251.52
11.36%
IN:METROPOLIS
Metropolis Healthcare Ltd.
2,126.70
144.85
7.31%
IN:NH
Narayana Hrudayalaya Ltd.
1,833.75
657.37
55.88%

Fortis Healthcare Ltd. Corporate Events

Fortis Healthcare Reports Debt Securities Issuance
Apr 10, 2025

Fortis Healthcare Limited has reported details of its debt securities issued through private placement, as per the SEBI Master Circular. The company has issued debt securities amounting to a total of 1,550 Crore INR, with a coupon rate of 8.486% for the first year, which will be reset annually. This announcement is significant for stakeholders as it reflects Fortis Healthcare’s financial strategies and commitments in the debt market, potentially impacting its financial stability and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025